ASCO 2024 | Advancements in prostate cancer therapies from ASCO 2024
Michael Morris, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the exciting developments in prostate cancer therapies presented at the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL. Dr Morris highlights the promising data on new bispecific antibodies and radioligand therapy, as well as advancements in optimizing chemotherapy and hormonal therapy for patients with prostate cancer. He describes the current period as a “blossoming” of innovative treatments, marking significant progress in the field. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
